These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21482682)

  • 1. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
    Permpoonpattana P; Hong HA; Phetcharaburanin J; Huang JM; Cook J; Fairweather NF; Cutting SM
    Infect Immun; 2011 Jun; 79(6):2295-302. PubMed ID: 21482682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
    Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
    Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile.
    Hong HA; Hitri K; Hosseini S; Kotowicz N; Bryan D; Mawas F; Wilkinson AJ; van Broekhoven A; Kearsey J; Cutting SM
    Infect Immun; 2017 Apr; 85(4):. PubMed ID: 28167669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
    Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
    BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.
    Ward SJ; Douce G; Figueiredo D; Dougan G; Wren BW
    Infect Immun; 1999 May; 67(5):2145-52. PubMed ID: 10225867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
    Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
    Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal Immunization with the C-Terminal Domain of Bcla3 Induced Specific IgG Production and Attenuated Disease Symptoms in Mice Infected with
    Maia AR; Reyes-Ramírez R; Pizarro-Guajardo M; Saggese A; Ricca E; Baccigalupi L; Paredes-Sabja D
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933117
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
    Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
    Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Chimeric Protein Vaccines Against
    Wang S; Wang Y; Cai Y; Kelly CP; Sun X
    Front Immunol; 2018; 9():2440. PubMed ID: 30405630
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.
    Torres JF; Lyerly DM; Hill JE; Monath TP
    Infect Immun; 1995 Dec; 63(12):4619-27. PubMed ID: 7591115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.
    Donald RGK; Flint M; Kalyan N; Johnson E; Witko SE; Kotash C; Zhao P; Megati S; Yurgelonis I; Lee PK; Matsuka YV; Severina E; Deatly A; Sidhu M; Jansen KU; Minton NP; Anderson AS
    Microbiology (Reading); 2013 Jul; 159(Pt 7):1254-1266. PubMed ID: 23629868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
    Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
    J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
    Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
    PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.
    Roberts A; McGlashan J; Al-Abdulla I; Ling R; Denton H; Green S; Coxon R; Landon J; Shone C
    Infect Immun; 2012 Feb; 80(2):875-82. PubMed ID: 22144483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
    Baliban SM; Michael A; Shammassian B; Mudakha S; Khan AS; Cocklin S; Zentner I; Latimer BP; Bouillaut L; Hunter M; Marx P; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
    Infect Immun; 2014 Oct; 82(10):4080-91. PubMed ID: 25024365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacy induced by recombinant Clostridium difficile toxin fragments.
    Leuzzi R; Spencer J; Buckley A; Brettoni C; Martinelli M; Tulli L; Marchi S; Luzzi E; Irvine J; Candlish D; Veggi D; Pansegrau W; Fiaschi L; Savino S; Swennen E; Cakici O; Oviedo-Orta E; Giraldi M; Baudner B; D'Urzo N; Maione D; Soriani M; Rappuoli R; Pizza M; Douce GR; Scarselli M
    Infect Immun; 2013 Aug; 81(8):2851-60. PubMed ID: 23716610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.
    Giannasca PJ; Zhang ZX; Lei WD; Boden JA; Giel MA; Monath TP; Thomas WD
    Infect Immun; 1999 Feb; 67(2):527-38. PubMed ID: 9916055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.